Covid-19 Update

Debate between Nadhim Zahawi and Neale Hanvey

Thursday 22nd July 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful to my hon. Friend for her excellent question and for the work that she does in her constituency to highlight the benefits of being vaccinated—and fully vaccinated. The work that has gone on in Hyndburn is tremendous. We are working with local government to ensure that the NHS has flexibility, whether that is to launch pop-up sites or to increase the hours of vaccination during this period of Eid celebration in order to encourage more of our Muslim fellow citizens to come forward and get vaccinated. Of course, we are ensuring that there is lots of messaging and that people are just pointed to information, including through hyper-local media as well as some of the media with which my hon. Friend’s generation will be more familiar than mine, such as TikTok, social media influencers and YouTubers. That is all happening at scale. It is great to see that the number of appointments booked under the national booking system has almost doubled in the last couple of days, but there are also the walk-in centres, where people can just walk in and get their jab without an appointment.

[Neale Hanvey (Kirkcaldy and Cowdenbeath) (Alba)]

Mr Speaker, may I add my party’s thanks to you, to the House staff and to everyone across these islands who has worked so hard to save and preserve life during the pandemic?

I want to pick up on a vital component of vaccination that I believe the Government need to give great attention to. It will not have escaped the Minister’s attention, and anyone who has attended the regular briefings that we have had around the virus will have seen in Professor Van-Tam’s heat maps the distribution and upward spread of the virus, whereby it seeds in the younger population and exponentially grows up through the ages.

I really want to ask the Minister why he thinks the JCVI are being extremely cautious in extending vaccination to 12 to 17-year-olds, given that the US Centres for Disease Control and Prevention has now been vaccinating that population in the States—with some concerns, but, I think, manageable numbers of concerns—and why we are not progressing more vigorously to vaccinate that population and are limiting it to those with underlying health concerns or those related to people with underlying health concerns. There is a fundamental advantage to vaccinating this group, because it will increase their wellbeing and improve their access to schooling after their holidays, but, more importantly, it acts as—

[Neale Hanvey]

I will finish now, Mr Speaker; I apologise.

Does the Minister not see the advantage of delivering those vaccines now, and what do we do if we decide that that needs to go live during the recess?

[Nadhim Zahawi]

That is a very important question. The JCVI is constantly reviewing the data from other countries that are vaccinating all children of 12 to 15 years old. Its concern has been centred around vaccinating healthy children. There is a very rare signal of myocarditis on first dose. The JCVI is awaiting more data on second dose. It will continue to review that and will come back to us, and, of course, we will come back to the House.

Covid-19 Update

Debate between Nadhim Zahawi and Neale Hanvey

Monday 19th July 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful to my hon. Friend for his excellent question. As I mentioned in my statement, an impact statement has been published today, and a full impact assessment will be made. Just to bring it to life for him, to reassure him and the House, I can say that Barchester Healthcare, one of the providers, has about 16,000 employees, so it is quite a large sample to look at, and it has implemented this policy early. When it consulted its workforce on the duty of deployment, it managed successfully to get the workforce to be vaccinated —they were on a priority list in phase 1 of the vaccination programme—and only 78 out of the workforce of 16,000, or about 0.5%, actually chose not to and no longer work for Barchester Healthcare. I hope that gives him some reassurance that we look at this data very carefully.

[Neale Hanvey (Kirkcaldy and Cowdenbeath) (Alba)]

I would like to pay tribute to the Minister for his work on probably the only functioning part of the Government’s response to covid, but all of that work is at risk because of the Prime Minister’s surrender strategy.

In my Kirkcaldy and Cowdenbeath constituency, I have one case—I will give it as an example—of a young girl who had eight negative lateral flow test results, but as she was symptomatic her parents insisted on a PCR test, and that was positive. A cluster has grown up around the young person and her family, and they are obviously in great distress not just because of her infection, but because of the consequences. So why do the Government, both here and in the devolved countries, persist in using discredited lateral flow devices that are not designed for use in asymptomatic subjects—they are designed for use in symptomatic subjects—and that are designed for use in the professional setting, not for self-administering that test? We have domestic tests that excel in both and that beat the current tests hands down, but they are not being contracted. Can the Minister please advise the House why the Government are blind to the domestic diagnostics industry?

[Nadhim Zahawi]

I thank the hon. Member for his question. I would just respectfully say that, on the contrary, the Government work with the diagnostics industry. Indeed, we were able to scale up. When we entered this pandemic, we were only capable of doing about 2,000 tests a day, but we now have a PCR testing capacity of 600,000, as he will have heard earlier, and millions of lateral flow tests. I think it is the combination of both those things that works, but if there are other companies in his constituency or indeed elsewhere in the country that he thinks are worth looking at, I will certainly put them through to the relevant team in the Department.

Covid-19

Debate between Nadhim Zahawi and Neale Hanvey

Tuesday 25th May 2021 Commons Chamber

[Nadhim Zahawi]

I join my hon. Friend in thanking the local team for going above and beyond, and, as I said earlier, it is all about that spirit of Dunkirk and the coming together of the nation to deliver the vaccination programme. A couple of weeks ago, the Prime Minister announced the therapeutics taskforce, which is moving at pace to identify therapeutics and antivirals to help people who, for whatever reason, cannot be vaccinated and to give us a greater arsenal in our armoury against this pandemic.

[Neale Hanvey (Kirkcaldy and Cowdenbeath) (Alba) [V]]

I get my second vaccine tomorrow, so I would also like to thank all of the NHS staff and other staff who have made this possible in such a quick turnaround. However, all of that cannot conceal the opacity of the UK Government’s position on accusations of cronyism and corruption, but, thanks to the Good Law Project, that is finally being challenged in the High Court this week. I have been attempting to get to the heart of the procurement of unlicensed lateral flow tests and been met with glib obfuscation from the Department. Can the Minister therefore tell me: when was the contract for these devices signed; was it known at the time that these tests were not licensed by the MHRA for asymptomatic testing; which Minister approved this contract; and if the Government really have nothing to hide, why do they just not come clean?

[Nadhim Zahawi]

I just remind the hon. Member that, at this Dispatch Box, the Prime Minister announced a full inquiry that will take place in the spring of 2022, where we can learn all the lessons of the covid pandemic and the Government’s response to it. Suffice to say that all contracting is published in the appropriate way, and civil servants follow the exact rules around contracting.

Covid-19 Vaccine Update

Debate between Nadhim Zahawi and Neale Hanvey

Thursday 4th February 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful to the Chair of the Health and Social Care Committee for his question, and he is absolutely right. The manufacturers are already working on variants to their vaccine to take into account the mutation of the virus. Viruses will mutate to survive and this virus is no different. There are about 4,000 mutations now around the world, some more concerning than others. We have, in the United Kingdom, a genome sequencing industry that is a world leader—about 50%, or just under, of the sequencing has taken place in the United Kingdom. Not only are we working with the current manufacturers—Pfizer-BioNTech, AstraZeneca and Moderna —that have been approved, but we are also looking at how we can make sure that we make the most of the new messenger RNA technology, which allows the rapid development of vaccine variants that will then deal with the virus variants as rapidly as possible. When I spoke to the Science and Technology Committee a few weeks ago, I said that we were planning to have in place the ability to go from the moment that we can sequence a variant that we are really concerned about to the moment that we can have a vaccine ready in between 30 to 40 days, with then, of course, the manufacturing time.

We have invested in Oxfordshire, in the Vaccines Manufacturing and Innovation Centre, and in the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Braintree—£127 million there and just shy of £100 million in Oxfordshire—to be ready to manufacture any vaccine that we would need. The Prime Minister, of course, also visited those making what I refer to as our seventh vaccine, the Valneva vaccine. That is a whole inactivated virus, so it does not just work on the spikes in the way that the two current vaccines that we are deploying work. It works on the whole of the virus, which is much more likely to capture any mutations from the spikes and therefore be incredibly effective. We have invested in that production facility in Scotland so that we can have that vaccine as a future-proofing of annual vaccination strategies or a booster in the autumn, if necessary.

[Neale Hanvey (Kirkcaldy and Cowdenbeath) (SNP) [V]]

I thank the Minister for advance sight of his statement. I am glad to hear his recognition of the importance of adherence to the clinical categories of the JCVI, and I also give my thanks to vaccination teams in my Kirkcaldy and Cowdenbeath constituency, across Scotland and, indeed, these islands.

I urge the Minister, however, to think more lightly of himself and deeply of the world. Over recent weeks, the UK Government and their allies in Scotland have quite disgracefully been attempting to sow fear in the minds of our vulnerable communities that vaccine deployment is too slow. That narrative was completely debunked yesterday, yet the Prime Minister still claimed that we have today passed the milestone of 10 million vaccines in the United Kingdom, including almost 90% of those aged 75 and over in England, and every eligible person in a care home. Today, however, on “Good Morning Scotland”, the Minister was further pressed on how many vaccines had been given—not offered, but given to people in care homes in England. Even with 24 hours’ warning and following a detailed probing, he was not able to offer more than a vague 91% of those eligible in an ill-defined subset, before settling on “a very high number”, and suggesting that care home staff’s vaccination may not yet have begun in England. Can he tell us today what percentage of all care home residents and all care home staff have had their jab in England and, if not, why not?

To return to the JCVI clinical prioritisation, in a recent written parliamentary question to the Minister regarding the clinically extremely vulnerable, he chose to regurgitate JCVI guidance rather than answering the question. With the encouraging news that the Oxford vaccine and potentially others have a measurable impact on transmission, can he update the House on what steps he has taken to ask the JCVI to review current guidance for household members of the clinically extremely vulnerable, such as people with blood cancer or organ transplantation, and thus provide a vital layer of protection to those who may not be able to receive the vaccine themselves?

[Nadhim Zahawi]

I am grateful for the hon. Member’s question, albeit, dare I say, I do not recognise his description of our collaboration. We have, over the past two weeks, been working solidly. The British Army—the armed forces—have been working to deliver 80 vaccination sites in Scotland and to hand them over to NHS Scotland within 28 days, and that work began a couple of weeks ago. So I hope he recognises the effort the United Kingdom is putting in not just in supplying the vaccines for Scotland, Wales, Northern Ireland and England, but in the way we are trying to support the vaccine deployment in Scotland.

Of course, last weekend was our target to make sure that every eligible care home in England was visited, and over 10,000 care homes have actually been visited and received the vaccine. Only a handful of care homes, which were deemed to have an outbreak, were not visited. The NHS, quite rightly, celebrated achieving that target last weekend, so I am slightly saddened, in a way, that there is this politicking between ourselves about this issue.

We continue—as the shadow Minister, the hon. Member for Nottingham North (Alex Norris), asked me—to work very hard to make sure that staff in care homes are also offered the vaccine on those visits, and they also have an opportunity to be vaccinated in their primary care networks and, of course, in hospitals.

On the JCVI, those who are clinically extremely vulnerable are in category 4, and we will vaccinate them by mid-February.